The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Rosiglitazone Induces Decreases in Bone Mass and Strength that Are Reminiscent of Aged Bone
Open accessAbstract
Peroxisome proliferator-activated receptor-gamma (PPARgamma) regulates both glucose metabolism and bone mass. Recent evidence suggests that the therapeutic modulation of PPARgamma activity with antidiabetic thiazolidinediones elicits unwanted effects on bone. In this study, the effects of rosiglitazone on the skeleton of growing (1 month), adult (6 month), and aged (24 month) C57BL/6 mice were determined. Aging was identified as a confounding factor for rosiglitazone-induced bone loss that correlated with the increased expression of PPARgamma in bone marrow mesenchymal stem cells. The bone of young growing mice was least affected, although a significant decrease in bone formation rate was noted. In both adult and aged animals, bone volume was significantly decreased by rosiglitazone. In adult animals, bone loss correlated with attenuated bone formation, whereas in aged animals, bone loss was associated with increased osteoclastogenesis, mediated by increased receptor activator of nuclear factor-kappaB ligand (RANKL) expression. PPARgamma activation led to changes in marrow structure and function such as a decrease in osteoblast number, an increase in marrow fat cells, an increase in osteoclast number, and a loss of the multipotential character of marrow mesenchymal stem cells. In conclusion, rosiglitazone induces changes in bone reminiscent of aged bone and appears to induce bone loss by altering the phenotype of marrow mesenchymal stem cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: Pluripotency of mesenchymal stem cells derived from adult marrow
Jiang, Y., Jahagirdar, B. N., Reinhardt, R. L., Schwartz, R. E., Keene, C. D., Ortiz-Gonzalez, X. R., Reyes, M., Lenvik, T., Lund, T., Blackstad, M., et al. (2002) · Nature · doi:10.1038/nature00870 · Cited by 5,518
RetractedParfitt, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. A., Malluche, H., Meunier, P. J., Ott, S. M., & Recker, R. R. (1987) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650020617 · Cited by 5,016
Bone Histomorphometry : Standardization of Nomenclature, Symbols, and Units
PARFITT, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. А., Malluche, H. H., Meunier, P. J., Ott, S. M., & Recker, R. R. (1987) · Journal of Bone and Mineral Research · Cited by 3,258
Genetic regulation of osteoclast development and function
Teitelbaum, S. L., & Ross, F. P. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1122 · Cited by 1,701
Lehrke, M., & Lazar, M. A. (2005) · Cell · doi:10.1016/j.cell.2005.11.026 · Cited by 1,443
The molecular understanding of osteoclast differentiation
Asagiri, M., & Takayanagi, H. (2007) · Bone · doi:10.1016/j.bone.2006.09.023 · Cited by 1,363
Muraglia, A., Cancedda, R., & Quarto, R. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.7.1161 · Cited by 1,024
Mechanisms of Disease: is osteoporosis the obesity of bone?
Rosen, C. J., & Bouxsein, M. L. (2006) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0070 · Cited by 956
PPAR γ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors
Akune, T., Ohba, S., Kamekura, S., Yamaguchi, M., Chung, U.-I., Kubota, N., Terauchi, Y., Harada, Y., Azuma, Y., Nakamura, K., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19900 · Cited by 869
Moerman, E. J., Teng, K., Lipschitz, D. A., & Lecka‐Czernik, B. (2004) · Aging Cell · doi:10.1111/j.1474-9728.2004.00127.x · Cited by 833
Self-citationTheoleyre, S., Wittrant, Y., Tat, S. K., Fortun, Y., Redini, F., & Heymann, D. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.06.004 · Cited by 663
Multilineage Transcriptional Priming and Determination of Alternate Hematopoietic Cell Fates
Laslo, P., Spooner, C. J., Warmflash, A., Lancki, D. W., Lee, H.-J., Sciammas, R., Gantner, B. N., Dinner, A. R., & Singh, H. (2006) · Cell · doi:10.1016/j.cell.2006.06.052 · Cited by 632
Peroxisome Proliferator–Activated Receptor γ and Metabolic Disease
Willson, T. M., Lambert, M. H., & Kliewer, S. A. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.341 · Cited by 582
Thiazolidinedione Use and Bone Loss in Older Diabetic Adults
Schwartz, A. V., Sellmeyer, D. E., Vittinghoff, E., Palermo, L., Lecka-Czernik, B., Feingold, K. R., Strotmeyer, E. S., Resnick, H. E., Carbone, L., Beamer, B. A., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2226 · Cited by 500
Self-citationRegulation of Osteoblast Formation and Function
Aubin, J. E. (2001) · Reviews in Endocrine and Metabolic Disorders · doi:10.1023/a:1010011209064 · Cited by 465
Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2.
Lecka‐Czernik, B., Gubrij, I. B., Moerman, E. J., Kajkenova, O., Lipschitz, D. A., Manolagas, S. C., & Jilka, R. L. (1999) · PubMed · Cited by 464
Self-citationBone Is a Target for the Antidiabetic Compound Rosiglitazone
Rzonca, S. O., Suva, L. J., Gaddy, D., Montague, D. C., & Lecka-Czernik, B. (2004) · Endocrinology · doi:10.1210/en.2003-0746 · Cited by 454
Self-citationRosiglitazone Causes Bone Loss in Mice by Suppressing Osteoblast Differentiation and Bone Formation
Ali, A. A., Weinstein, R. S., Stewart, S. A., Parfitt, A. M., Manolagas, S. C., & Jilka, R. L. (2005) · Endocrinology · doi:10.1210/en.2004-0735 · Cited by 444
Lecka-Czernik, B., Moerman, E. J., Grant, D. F., Lehmann, J. M., Manolagas, S. C., & Jilka, R. L. (2002) · Endocrinology · doi:10.1210/endo.143.6.8834 · Cited by 441
Self-citationParfitt, A. M. (1984) · Calcified Tissue International · doi:10.1007/bf02406145 · Cited by 441
Ren, D., Collingwood, T. N., Rebar, E. J., Wolffe, A. P., & Camp, H. S. (2002) · Genes & Development · doi:10.1101/gad.953802 · Cited by 362
Red and yellow marrow in the femur: age-related changes in appearance at MR imaging.
Moore, S. G., & Dawson, K. L. (1990) · Radiology · doi:10.1148/radiology.175.1.2315484 · Cited by 332
Changes in Bone Structure and Mass With Advancing Age in the Male C57BL/6J Mouse
Halloran, B. P., Ferguson, V. L., Simske, S. J., Burghardt, A., Venton, L. L., & Majumdar, S. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.6.1044 · Cited by 302
Fehrer, C., & Lepperdinger, G. (2005) · Experimental Gerontology · doi:10.1016/j.exger.2005.07.006 · Cited by 267
Kim, S., Yamazaki, M., Zella, L. A., Shevde, N. K., & Pike, J. W. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00353-06 · Cited by 222
Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis
Sorocéanu, M. A., Miao, D., Bai, X.-Y., Su, H., Goltzman, D., & Karaplis, A. C. (2004) · Journal of Endocrinology · doi:10.1677/joe.1.05723 · Cited by 199
Cao, J. J., Wronski, T. J., Iwaniec, U., Phleger, L., Kurimoto, P., Boudignon, B., & Halloran, B. P. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050503 · Cited by 195
Sottile, V., Seuwen, K., & Kneissel, M. (2004) · Calcified Tissue International · doi:10.1007/s00223-004-0224-8 · Cited by 178
Fu, Q., Manolagas, S. C., & O'Brien, C. A. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00356-06 · Cited by 166
Bendixen, A. C., Shevde, N. K., Dienger, K. M., Willson, T. M., Funk, C. D., & Pike, J. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.041493198 · Cited by 161
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ∞ AND METABOLIC DISEASE
Willson, T. M., Lambert, M. H., & Kliewer, S. A. (2001) · Cited by 154
Pattern of gene expression following rat tibial marrow ablation
Suva, L. J., Seedor, G., Endo, N., Quartuccio, H. A., Thompson, D. D., Bab, I., & Rodan, G. A. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080315 · Cited by 146
Self-citationLecka‐Czernik, B., Ackert‐Bicknell, C. L., Adamo, M. L., Marmolejos, V., Churchill, G. A., Shockley, K. R., Reid, I. R., Grey, A. B., & Rosen, C. J. (2006) · Endocrinology · doi:10.1210/en.2006-1121 · Cited by 139
Self-citationNetoglitazone is a PPAR-gamma ligand with selective effects on bone and fat
Lazarenko, O. P., Rzońca, S., Suva, L. J., & Lecka‐Czernik, B. (2005) · Bone · doi:10.1016/j.bone.2005.07.008 · Cited by 130
Self-citationEnhanced bone formation in lipodystrophic PPARγhyp/hyp mice relocates haematopoiesis to the spleen
Cock, T., Back, J., Elefteriou, F., Karsenty, G., Kastner, P., Chan, S. H., & Auwerx, J. H. (2004) · EMBO Reports · doi:10.1038/sj.embor.7400254 · Cited by 122
Osteoclasts, macrophages, and the molecular mechanisms of bone resorption
Teitelbaum, S. L., Tondravi, M. M., & Ross, F. P. (1997) · Journal of Leukocyte Biology · doi:10.1002/jlb.61.4.381 · Cited by 115
A Review of Rosiglitazone in Type 2 Diabetes Mellitus
Werner, A. L., & Travaglini, M. T. (2001) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.21.13.1082.34615 · Cited by 106
Thiazolidinediones Inhibit Osteoclast-Like Cell Formation and Bone Resorption in Vitro1
Okazaki, R., Toriumi, M., Fukumoto, S., Miyamoto, M., Fujita, T., TANAKA, K., & Takeuchi, Y. (1999) · Endocrinology · doi:10.1210/endo.140.11.7116 · Cited by 105
Ogawa, S., Urano, T., Hosoi, T., Miyao, M., Hoshino, S., Fujita, M., Shiraki, M., Orimo, H., Ouchi, Y., & Inoue, S. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0896 · Cited by 102
PPAR agonists modulate human osteoclast formation and activity in vitro
Chan, B. Y., Gartland, A., Wilson, P. J. M., Buckley, K. M., Dillon, J. P., Fraser, W. D., & Gallagher, J. A. (2006) · Bone · doi:10.1016/j.bone.2006.07.029 · Cited by 79
Silverstein, J. H., & Rosenbloom, A. L. (2001) · Current Diabetes Reports · doi:10.1007/s11892-001-0006-x · Cited by 65
Cellular and molecular mechanisms of osteoporosis
Manolagas, S. C. (1998) · Aging Clinical and Experimental Research · doi:10.1007/bf03339652 · Cited by 55
Stimulation of Resorption in Cultured Mouse Calvarial Bones by Thiazolidinediones
Schwab, A., Granholm, S., Persson, E., Wilkes, B., Lerner, U. H., & Conaway, H. H. (2005) · Endocrinology · doi:10.1210/en.2005-0601 · Cited by 29
Cited by
Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment
Naveiras, O., Nardi, V., Wenzel, P. L., Hauschka, P. V., Fahey, F., & Daley, G. Q. (2009) · Nature · doi:10.1038/nature08099 · Cited by 1,129
Aging and bone loss: new insights for the clinician
Demontiero, O., Vidal, C., & Duque, G. (2012) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x11430858 · Cited by 559
Wei, W., Dutchak, P. A., Wang, X., Ding, X., Wang, X., Bookout, A. L., Goetz, R., Mohammadi, M., Gerard, R. D., Dechow, P. C., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200797109 · Cited by 426
Use of Thiazolidinediones and Fracture Risk
Meier, C., Kraenzlin, M. E., Bodmer, M., Jick, S. S., Jick, H., & Meier, C. R. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.8.820 · Cited by 355
PPARγ: a circadian transcription factor in adipogenesis and osteogenesis
Kawai, M., & Rosen, C. J. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.155 · Cited by 323
Metadata
- Authors
- Lazarenko, O. P., Rzonca, S. O., Hogue, W. R., Swain, F. L., Suva, L. J., & Lecka-Czernik, B.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2007-06
- Volume
- 148
- Issue
- 6
- Pages
- 2669-2680
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2105700895
- Cited by
- 302
- References
- 43
- FWCI
- 11.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.